These findings illustrate potential therapeutic avenues for treating IBD, particularly UC, by targeting the CXCL12/CXCR4 chemokine axis, offering new avenues for intervention in this complex inflammatory condition. This evidence concerns the gene CXCL12 and inflammatory bowel disease.